Technology
Health
Biotechnology

Diffusion Pharmaceuticals

$4.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-1.06%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell DFFN and other stocks, options, ETFs, and crypto commission-free!

About

Diffusion Pharmaceuticals Inc. Common Stock, also called Diffusion Pharmaceuticals, is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. Read More The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Employees
10
Headquarters
Charlottesville, Virginia
Founded
2001
Market Cap
15.68M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
96.53K
High Today
$4.78
Low Today
$4.36
Open Price
$4.78
Volume
42.97K
52 Week High
$11.00
52 Week Low
$1.83

Collections

Technology
Health
Biotechnology
Medical
Research And Development
Cancer Prevention
2018 IPO
US

News

MarketBeatMar 4

Stock Price, News, & Analysis for Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pa...

239
Simply Wall StFeb 16

Does Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Have A High Beta?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first type is company specific...

840

Earnings

-$0.90
-$0.62
-$0.34
-$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.90 per share
Actual
-$0.06 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.